<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04428554</url>
  </required_header>
  <id_info>
    <org_study_id>19 URO 15</org_study_id>
    <nct_id>NCT04428554</nct_id>
  </id_info>
  <brief_title>Consolidative Radiotherapy Versus Observation for Metastatic Urothelial Bladder Cancer Patients Without Progression and With no More Than Three Residual Metastatic Lesions Following First Line Systemic Therapy</brief_title>
  <acronym>BLAD-RAD01</acronym>
  <official_title>Consolidative Radiotherapy Versus Observation for Metastatic Urothelial Bladder Cancer Patients Without Progression and With no More Than Three Residual Metastatic Lesions Following First Line Systemic Therapy: a Prospective Randomized Comparative Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Claudius Regaud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Claudius Regaud</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II, multicenter, randomized open-label and comparative study designed to
      evaluate whether local consolidative radiotherapy improves overall survival as compared with
      standard management in patients with limited metastatic urothelial bladder cancer and without
      progression following first-line systemic therapy.

      Each patient will be followed during 3 years from the date of randomization.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 30, 2020</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>3 years for each patient</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>3 years for each patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety will be assessed by the toxicity grading of the National Cancer Institute (NCI-CTCAE v5)</measure>
    <time_frame>3 years for each patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life will be evaluated by the EORTC QLQ-C-30 questionnaire</measure>
    <time_frame>3 years for each patient</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Urothelial Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Observation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Experimental arm</intervention_name>
    <description>Consolidative radiotherapy +/- transurethral resection of bladder tumor</description>
    <arm_group_label>Experimental arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18 years

          2. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2

          3. Urothelial bladder cancer histologically proven (both pure urothelial cancers and
             mixed histologic features are allowed)

          4. Metastatic patients (AJCC v8: M1a or M1b) documented with contrast-enhanced CT-scanner
             of the chest, abdomen and pelvis, either de novo or presenting first distant relapse
             following cystectomy (with no local recurrence in the cystectomy bed) more than 6
             months after completion of peri-operative chemotherapy

          5. Completion of the 1st line metastatic treatment (systemic therapy by chemotherapy
             and/or immunotherapy by immune check-point inhibitor according to standard
             recommendations)

          6. No disease progression after standard first-line systemic therapy according to RECIST
             v1.1

          7. No more than 3 residual metastatic lesions following standard first-line systemic
             therapy:

               1. The number of residual lesions is determined on the basis of the imaging modality
                  for tumor response assessment performed after systemic treatment according to
                  local habits (CT-scan or 18FDG PET-CT if performed):

                  In case of response assessment by CT-scanner only: residual lesions are all
                  remaining visible lesions

                  In case of response assessment by additional 18FDG PET-CT: residual lesions are
                  only the lesions with residual hyperfixation

               2. Regarding distant lymph nodes metastases:

             If evaluation is performed by CT-scanner only, residual lymph nodes are considered
             pathological according to one or several criteria among:

               -  Short axis ≥ 1cm

               -  Central necrosis

               -  Heterogeneous contrast enhancement

             Residual para-aortic nodes involvement accounts for one lesion, even if several
             para-aortic nodes are involved.

             Other nodes: each involved node accounts for one lesion.

          8. Residual metastases (if applicable) eligible for SBRT in terms of dose constraints to
             the organs at risk, with no prior radiotherapy interfering with SBRT

          9. 6 weeks or less between last cycle of systemic treatment and randomization

         10. No contraindication to pelvic radiotherapy

         11. Signed informed consent

         12. Patient able to participate and willing to give informed consent prior performance of
             any study-related procedures and to comply with the study protocol

         13. Patient affiliated to a Social Health Insurance in France.

        Exclusion Criteria:

          1. Non-transitional cell histology (Squamous cell carcinoma, adenocarcinoma or
             neuroendocrine carcinoma of the bladder)

          2. Brain metastases before systemic treatment

          3. Liver metastases before systemic treatment

          4. Absence of target to be irradiated (i.e. previous cystectomy + no residual lesions
             following systemic treatment + no pelvic or para-aortic nodes at metastatic
             presentation)

          5. Patient with relapse following definitive chemoradiation of the bladder

          6. Local recurrence in the cystectomy bed following cystectomy

          7. Previous pelvic irradiation

          8. Prior radiotherapy near the residual metastatic lesions precluding ablative SBRT

          9. Active inflammatory bowel disease

         10. Contraindication to SBRT of a lesion due to organ dysfunction; in particular, patients
             with lung lesions and documented or suspected interstitial lung disease should not be
             included

         11. History of scleroderma

         12. Current or past history of second neoplasm diagnosed within the last 5 years (except
             basocellular carcinoma and prostate cancer incidentally discovered during previous
             cystoprostatectomy and pelvic lymph node dissection and with a good prognosis [T stage
             &lt;pT3b and Gleason &lt;8 and pN- and post-operative PSA &lt;0.1 ng/mL])

         13. Pregnancy or breast feeding or inadequate contraceptive measures

         14. Known psychiatric or substance abuse disorders that would interfere with cooperation
             with the requirements of the trial

         15. Any psychological, familial, geographic or social situation, according to the judgment
             of investigator, potentially preventing the provision of informed consent or
             compliance to study procedure

         16. Patient who has forfeited his/her freedom by administrative or legal award or who is
             under legal protection (curatorship and guardianship, protection of justice)

         17. Concurrent enrolment in another interventional therapeutic clinical study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jonathan KHALIFA</last_name>
    <phone>05 31 15 54 01</phone>
    <email>khalifa.jonathan@iuct-oncopole.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinique Claude Bernard</name>
      <address>
        <city>Albi</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurent VOTRON</last_name>
      <phone>05 63 77 77 56</phone>
      <email>votron@claude-bernard-albi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie de L'Ouest</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nathalie MESGOUEZ-NEBOUT</last_name>
      <phone>02 41 35 27 00</phone>
      <email>thalie.mesgouez-nebout@ico-unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne Marie TESSIER</last_name>
      <phone>05 56 33 04 49</phone>
      <email>a.tessier@bordeaux.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu Morvan</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ulrike SCHICK</last_name>
      <email>ulrike.schick@chu-brest.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Francois Baclesse</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emmanuel MEYER</last_name>
      <phone>02 31 45 50 50</phone>
      <email>e.meyer@baclesse.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Genevieve LOOS</last_name>
      <phone>04 73 27 81 42</phone>
      <email>genevieve.loos@clermont.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David PASQUIER</last_name>
      <phone>03 20 29 51 44</phone>
      <email>d-pasquier@o-lambret.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Paoli-Calmettes</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Naji SALEM</last_name>
      <phone>04 91 22 36 37</phone>
      <email>salemn@ipc.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie de L'Ouest</name>
      <address>
        <city>Saint-Herblain</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Valentine GUIMAS</last_name>
      <phone>02 40 57 99 55</phone>
      <email>valentine.guimas@ico.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie Lucien Neuwirth</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicolas MAGNE</last_name>
      <phone>04 77 91 74 25</phone>
      <email>nicolas.magne@icloire.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire du Cancer Toulouse Oncopole</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan KHALIFA</last_name>
      <phone>05 31 15 54 29</phone>
      <email>khalifa.jonathan@iuct-oncopole.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre BLANCHARD</last_name>
      <phone>01 42 11 44 13</phone>
      <email>pierre.blanchard@gustaveroussy.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 9, 2020</study_first_submitted>
  <study_first_submitted_qc>June 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2020</study_first_posted>
  <last_update_submitted>July 3, 2020</last_update_submitted>
  <last_update_submitted_qc>July 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Urothelial bladder cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

